News &amp; Updates

Supplementation with either vitamin D3 or omega-3 fatty acid falls short of reducing the risk of frailty in older adults as compared with placebo, as shown in the ancillary study of the Vitamin D and Omega-3 (VITAL) trial.

Vitamin D3 or omega-3 supplementation of no help in frailty prevention in older adults

Piperacillin-tazobactam combo causes no delay in MTX clearance

Co-administration of piperacillin and tazobactam (PIPC/TAZ) does not result in delayed methotrexate (MTX) clearance during high-dose MTX therapy, a study has shown. In addition, co-administration of cefepime with high-dose MTX had no impact on MTX clearance.

Piperacillin-tazobactam combo causes no delay in MTX clearance

High-dose treprostinil for PH-ILD yields better outcomes

In the treatment of patients with pulmonary hypertension (PH) with fibrotic interstitial lung disease (ILD), a higher dose of inhaled treprostinil or getting at least nine breaths four times daily increases the likelihood of achieving clinical improvement and preventing clinical worsening, according to a study.

High-dose treprostinil for PH-ILD yields better outcomes

Evolocumab benefits build up in FOURIER OLE

19 Sep 2022 by

Early, long-term lipid lowering with the PCSK9 inhibitor evolocumab further reduces cardiovascular (CV) events, including CV death, without any safety signal, in the FOURIER* open-label extension (OLE) study.

Evolocumab benefits build up in FOURIER OLE

Tucatinib-trastuzumab combo induces durable tumour response in HER2+ mCRC

19 Sep 2022 by

Dual HER-2 inhibition with tucatinib and trastuzumab induces clinically meaningful and durable responses in patients with previously treated metastatic HER2-positive colorectal cancer (mCRC) in the phase II MOUNTAINEER trial, boosting hopes for this chemotherapy-free combination.

Tucatinib-trastuzumab combo induces durable tumour response in HER2+ mCRC

$Pharmacist-led program improves management of refractory chemo-induced nausea, vomiting$

Pharmacist-led program improves management of refractory chemo-induced nausea, vomiting

Implementing a clinical pharmacist-led service program has led to the standardization and streamlining of refractory chemotherapy-induced nausea and vomiting (CINV) management in adult haematology and oncology clinics, reports a study.

Pharmacist-led program improves management of refractory chemo-induced nausea, vomiting

SGLT2 inhibitors help prevent new-onset AF in diabetic Asians

Use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) may reduce the risk of new-onset atrial fibrillation (AF) relative to glucagon-like peptide-1 receptor agonists (GLP-1RAs) in Asian patients with type 2 diabetes mellitus (T2DM) in a real-world practice, reports a recent study.

SGLT2 inhibitors help prevent new-onset AF in diabetic Asians

18 Sep 2022

Vitamin C infusion in ICU-admitted patients: Any benefit?

18 Sep 2022 by

The administration of intravenous vitamin C to patients with sepsis admitted to the intensive care unit (ICU) did not result in a reduced risk of death or organ dysfunction, according to results of the phase III LOVIT* trial.

Vitamin C infusion in ICU-admitted patients: Any benefit?

AF patients with high comorbidity may benefit from early rhythm control

Early rhythm control (ERC) appears to cut the risk of adverse cardiovascular outcomes in atrial fibrillation (AF) patients with a CHA2DS2-VASc score of ≥4, a study has found.

AF patients with high comorbidity may benefit from early rhythm control

Eribulin less effective in real-world HER2-negative metastatic breast cancer than in trials

The real-world effectiveness of eribulin in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer is lower than that seen in clinical trials, reveals a study.

Eribulin less effective in real-world HER2-negative metastatic breast cancer than in trials